A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418

Phase 1 Recruiting 64 enrolled 1ST Biotherapeutics, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of oral doses of FB418 in healthy adult subjects and healthy elderly subjects.

Timeline

Start: 2023-12-20
Primary completion: 2024-12
Completion: 2024-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FB418	Unknown	—	Oral

A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418

Summary

Timeline

Drugs

Indications